Abstract

Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.

Details

Title
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Author
Chiavelli, Chiara 1   VIAFID ORCID Logo  ; Prapa, Malvina 1   VIAFID ORCID Logo  ; Rovesti, Giulia 2   VIAFID ORCID Logo  ; Silingardi, Marco 3 ; Neri, Giovanni 3   VIAFID ORCID Logo  ; Pugliese, Giuseppe 4   VIAFID ORCID Logo  ; Trudu, Lucia 2 ; Dall’Ora, Massimiliano 5 ; Golinelli, Giulia 6   VIAFID ORCID Logo  ; Grisendi, Giulia 1 ; Vinet, Jonathan 7 ; Bestagno, Marco 8   VIAFID ORCID Logo  ; Spano, Carlotta 9 ; Papapietro, Roberto Vito 10 ; Depenni, Roberta 10 ; Di Emidio, Katia 10 ; Pasetto, Anna 11   VIAFID ORCID Logo  ; Nascimento Silva, Daniela 12 ; Feletti, Alberto 13 ; Berlucchi, Silvia 14 ; Iaccarino, Corrado 14 ; Pavesi, Giacomo 14 ; Dominici, Massimo 15   VIAFID ORCID Logo 

1  University of Modena and Reggio Emilia, Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570) 
2  University of Modena and Reggio Emilia, Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570); University of Modena and Reggio Emilia, Clinical and Experimental Medicine PhD Program, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570); University-Hospital of Modena and Reggio Emilia, Department of Oncology and Hematology, Modena, Italy (GRID:grid.413363.0) (ISNI:0000 0004 1769 5275) 
3  University of Modena and Reggio Emilia, Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570); University of Modena and Reggio Emilia, Clinical and Experimental Medicine PhD Program, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570) 
4  University of Modena and Reggio Emilia, Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570); University-Hospital of Modena and Reggio Emilia, Department of Oncology and Hematology, Modena, Italy (GRID:grid.413363.0) (ISNI:0000 0004 1769 5275); Great Maze Pond, Leucid Bio Ltd., Guy’s Hospital, London, UK (GRID:grid.239826.4) (ISNI:0000 0004 0391 895X) 
5  Evotec (Modena) Srl, Medolla, Modena, Italy (GRID:grid.413363.0) 
6  University of Modena and Reggio Emilia, Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570); Perelman School of Medicine, and Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Center for Cellular Immunotherapies, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
7  University of Modena and Reggio Emilia, Centro Interdipartimentale Grandi Strumenti (CIGS), Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570) 
8  International Centre for Genetic Engineering and Biotechnology, Trieste, Italy (GRID:grid.425196.d) (ISNI:0000 0004 1759 4810) 
9  University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570) 
10  University-Hospital of Modena and Reggio Emilia, Department of Oncology and Hematology, Modena, Italy (GRID:grid.413363.0) (ISNI:0000 0004 1769 5275) 
11  Oslo University Hospital, Section for Cell Therapy, Radiumhospitalet, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); Karolinska Institutet, Department of Laboratory Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
12  Karolinska Institutet, Department of Laboratory Medicine, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
13  University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Neurosurgery Unit, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124) 
14  University-Hospital of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia - Division of Neurosurgery, Department of Neurosciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570) 
15  University of Modena and Reggio Emilia, Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570); University-Hospital of Modena and Reggio Emilia, Department of Oncology and Hematology, Modena, Italy (GRID:grid.413363.0) (ISNI:0000 0004 1769 5275) 
Pages
26
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
2397768X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41698-024-00506-z
ProQuest document ID
2920959453
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.